PARIS and NEW YORK, Aug. 31 /PRNewswire-FirstCall/ -- Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb (New York: NYSE: BMY) (the "companies") today announced that the U.S.

PARIS, and NEW YORK, Aug. 14 /PRNewswire-FirstCall/ -- Sanofi-aventis (Paris Bourse: EURONEXT: SAN) and Bristol-Myers Squibb (the "companies") today moved for a preliminary injunction ordering Apotex Inc. and Apotex Corp.

By THERESA AGOVINO and WALLACE WITKOWSKI NEW YORK - Shares of Bristol-Myers Squibb Co. sank more than 6 percent Tuesday as a generic drug maker disclosed it has begun selling a cheaper version of the big pharmaceutical company's best-selling drug Plavix. Apotex Corp.

PARIS, NEW YORK and TORONTO, June 25 /PRNewswire-FirstCall/ -- Sanofi- aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol- Myers Squibb (the"companies") and Apotex Inc. and Apotex Corp.

Apotex Corp. today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for zonisamide capsules in 25 mg, 50 mg and 100 mg strengths. Shipments of the product will commence immediately.